.Anavex Life Sciences’ lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial, with the company pointing the blame toward a high placebo effect.The New York City-based biotech's stock cratered 30% since the data was shared earlier today, tumbling from $9.32 per share at market close Friday to $6.55 as of 10:30 a.m. ET.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-96
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.27 |
Change
-1.370(6.33%) |
Mkt cap ! $2.588B | |||
| Open | High | Low | Value | Volume |
| $21.62 | $21.63 | $20.24 | $11.01M | 531.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1111 | $20.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.28 | 338 | 1 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.37 |
Change
-1.370 ( 5.24 %) |
||||
| Open | High | Low | Volume | ||
| $21.61 | $21.62 | $20.25 | 138748 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| NEU (ASX) Chart |